Skip to content

The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients

The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
PACTR
Registry ID
PACTR202408492665945
Enrollment
135
Registered
2024-08-13
Start date
2024-06-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute aluminum phosphide toxicity

Interventions

Sponsors

Tanta University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? All symptomatic acute ALP poisoned patients aged 12 years or older (male and female). ? Patients admitted within 2 hours of exposure. Diagnosis will be based on the following: - History of exposure from the patient and or his/her relatives, -Availability of tablets container brought by the patient’s relatives, -Suggestive clinical manifestations (symptoms and signs).

Exclusion criteria

Exclusion criteria: ? Patients aged less than 12 years old. ? Delayed time of presentation more than 2 hours. ? Patients with history of chronic comorbidities like cardiovascular disease, chronic kidney disease, chronic liver disease, diabetes and chronic pulmonary disease. ? Patients with mixed ingestion. ? Patients received any medical intervention before admission. ? Pregnant and lactating women. ? Patients with known hypersensitivity to sevelamer or any of its constituents. ? Patients who have bowel obstruction, active dysphagia, swallowing disorder, ileus, or severe gastrointestinal motility disorders including severe constipation, fecal impaction and bowel perforation. ? Patients who are using anti-arrhythmic or anti-seizure medications

Design outcomes

Primary

MeasureTime frame
Mortality rate.

Secondary

MeasureTime frame
Need for intubation or intensive care unit admission.;Duration of hospital stay.;Total dose of vasopressors.;Arterial blood pressure.;Arterial blood gas parameters.

Countries

Egypt

Contacts

Public ContactAsmaa Gamal Salah

Assistant Lecturer of Forensic Medicine and Clinical Toxicology Department Faculty of Medicine Tanta University

asmaa.gamal93@med.tanta.edu.eg01094691133

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026